Newsletter
| Promoter: | pennyomega.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| CYTR | Unknown compensation | UNKNOWN |
| Max Profit: 0.47 % | Gain at close: -3.28 % | |
| *We think that this promoter is a part of a group of promoters. | ||
Positive Interim Results from Soft Tissue Sarcoma Trial
CytRx Corporation (CYTR)
A sarcoma is a type of cancer that begins in any part of the body, such as the bone or soft tissue. Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. They can arise anywhere in the body at any age.
The American Cancer Society's estimates for soft tissue sarcomas in the United States for 2014 are (these statistics include both adults and children):
* About 12,020 new soft tissue sarcomas will be diagnosed (6,550 cases in males and 5,470 cases in females).
* 4,740 Americans (2,550 males and 2,190 females) are expected to die of soft tissue sarcomas.
CYTR reported updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with soft tissue sarcomas
CYTR holds the exclusive worldwide rights to aldoxorubicin.
CYTR is a biopharmaceutical research and development company specializing in oncology.
More about CytRx Corporation (CYTR) at www.cytrx.com.
**
FormFactor, Inc. (FORM)
FORM was upgraded from Neutral to Buy and a price target of $8.50 per share by brokerage firm B. Riley
FORM has raised its guidance, driven by customer demand across the SOC and the DRAM segments.
FORM expects revenue for its fiscal second quarter of 2014 to be between $65 and $69 million, higher than its previous revenue guidance of $62 to $66 million, while Non-GAAP gross margin is expected to be between 34% to 37%, higher than FORM's previous gross margin guidance of 31% to 34%.
FORM is a leader in advanced wafer test solutions. Its advanced wafer probe cards enable semiconductor manufacturers to lower their overall production costs, improve yields, and bring next-generation devices to market.
More about FormFactor Inc. (FORM) at www.formfactor.com.
**
General Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Statements on this website or newsletter may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained on this website. The Company disclaims any obligation to update any statements in this website. These stock quotes and related data are provided for information purposes only and are not intended for trading purposes. Crown Equity Holdings Inc. will not be liable for any inaccuracies or delays in such data, or for any actions taken in reliance thereon. Potential investors should seek independent information and advice from qualified investment professionals prior to investment. Crown Equity Holdings Inc. provides links to websites operated by third parties. These links may be of interest or of use to you, and are provided for convenience only. You should be aware that in using these links, you are leaving Crown Equity Holdings Inc’s website. Crown Equity Holdings Inc. does not approve or endorse the content, information or materials available on such third party websites. In addition, Crown Equity Holdings Inc. makes no representation regarding, and is not responsible for, the content, information or material available on such websites. If you decide to access such websites or newsletter you do this at your own risk, and Crown Equity Holdings Inc. will not be liable for any loss or damage associated with your use of, or reliance on, the content, information or material available on such website.